How did you decide to participate in the Biomapas Academy?
When I used to walk past a pharmacy every day, I could never stop dreaming about being able to help people and develop innovative pharmaceuticals. So while studying biomedical sciences, I became interested in the drug development paths, which led me to medicinal chemistry. And one day at the university, I saw a poster about the Biomapas Academy, which could help me understand what, how, where, and when happens to pharmaceutical products during the whole journey to reach us, so I signed up for it without hesitation. Even though I am usually not a lucky person, I was selected to be one of the participants, which surprised me!
How was your experience regarding the Academy?
During the few months, I deepened my existing knowledge of drug development stages and expanded it to learn more about drug regulation and pharmacovigilance. After graduating from the Academy, I got the opportunity to try out regulatory affairs as part of Biomapas – I completed a summer internship in the Regulatory Affairs department.
How do you feel after graduating from the Academy?
I will never forget this practice in my life, not only because it fulfilled what I was looking for, but it let me realize that I want to return to this company after my graduation and put my accumulated knowledge to use. Thanks again to all Biomapas staff for their insights and advice, and I hope to see you soon.
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
Pharmacovigilance Auditing: Understanding the Process and Maximizing Its Benefits
Discover how pharmacovigilance audits go beyond compliance to uncover hidden risks, drive improvement, and ensure every patient gets the safest treatment possible.
Diversity in Clinical Trials: A European Perspective on Global Progress and Strategies
In light of recent developments, we must recognise that diversity in clinical trials is not just a buzzword anymore, it is a key priority. Yet, with varying perspectives from regulatory agencies worldwide, and an industry still unaligned on the best approaches, there...
All you need to know about the FDA’s Draft Guidance on Diversity Action Plans
The U.S. Food and Drug Administration’s (FDA) draft guidance on Diversity Action Plans (DAPs) is a significant step towards addressing the underrepresentation of diverse populations in clinical research. Released in June 2024, this guidance aligns with broader efforts...
Biomapas Announces Strategic Partnership to Drive Future Growth
Carbyne Equity Partners has signed to acquire majority ownership in UAB Biomapas.
Diversity in Clinical Trials: Significance & Challenges
Diversity in Clinical Trials: Significance & Challenges By Jan Filakovsky, CEO of BiomapasDiversity in clinical trials is crucial in ensuring that research findings are broadly applicable, and in avoiding treatments that are ineffective or even harmful to...
Partnering for Success: Specialised Rescue Studies in Georgia
Discover the benefits of conducting clinical trials in Georgia through this case study of three pharmaceutical companies.
Unlocking Success: The FSP Advantage in Clinical Research
The Functional Service Provider (FSP) models in clinical research are becoming increasingly appealing to the pharmaceutical and biotechnology sectors, offering flexible and scalable solutions to outsource specific functions . Currently pharmaceutical and...
Literature monitoring of Pharmacovigilance in realities of war in Ukraine
The need for continuous monitoring of drug safety in a country at war, and the ability to adapt to the circumstances for ensuring the safety of patients, is critical.
Bridging Gaps in Clinical Trials: Enhanced Access & Embracing Diversity
Explore the crucial role of diversity and accessibility in clinical research in this insightful article.
Pharmacovigilance & CSV: System Upgrades
Explore the intersection of Pharmacovigilance & CSV during system upgrades. Ensure drug safety while optimizing computer system validation.
